We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Gene Identified That Promotes Childhood Cancers

By LabMedica International staff writers
Posted on 03 Sep 2014
A gene has been identified that contributes to the development of several childhood cancers and this could lead to new strategies for targeting certain childhood cancers at a molecular level. More...


Ribonucleic acid (RNA)-binding proteins that influence stem cell maintenance, metabolism, and oncogenes, and in poorly differentiated, aggressive cancers are often overexpressed, have their role in tumor initiation or maintenance not definitively addressed.

Scientists at The University of Texas Southwestern Medical Center (Dallas, TX, USA) used a murine model to study the RNA-binding proteins Lin28a/b. The Lin-28 Homolog B gene (LIN28B) overexpression is sufficient to initiate hepatoblastoma and hepatocellular carcinoma in murine models. The team also detected LIN28B overexpression in V-Myc Avian Myelocytomatosis Viral Oncogene Homolog (MYC)-driven hepatoblastomas, and liver-specific deletion of Lin28a/b reduced tumor burden, extended latency, and prolonged survival.

Insulin-like growth factor 2 mRNA binding protein (Igf2bp) proteins are upregulated, and the gene Igf2bp3 is required in the context of LIN28B overexpression to promote growth. Therefore, the multiple murine models demonstrate that LIN28B is both sufficient to initiate liver cancer and necessary for its maintenance. Both intravenous small interfering RNA (siRNA) against LIN28B and conditional LIN28B deletion reduced tumor burden and prolonged survival.

Hao Zhu, MD, a professor of Pediatrics and Internal Medicine and senior author of the study said. “We and others have found that LIN28B—a gene that is normally turned on in fetal but not adult tissues—is expressed in several childhood cancers, including neuroblastoma, Wilms' tumor, and hepatoblastoma, a type of cancer that accounts for nearly 80% of all liver tumors in children. In our study, we found that overproduction of LIN28B specifically causes hepatoblastoma, while blocking LIN28B impairs the cancer's growth. This opens up the possibility that pediatric liver cancer patients could one day be treated without resorting to chemotherapy.” The study was published on August 11, 2014, in the journal Cancer Cell.

Related Links:

The University of Texas Southwestern Medical Center 



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
New
Gastrointestinal Panel
Xpert® GI Panel
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: LVOne uses blood-based biomarkers to detect stroke and identify large vessel occlusion before hospital arrival, providing objective results earlier than traditional assessments. (Photo courtesy of UpFront Diagnostics)

First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage

Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: RealTime Labs’ Mycotoxin Extensive Panel measures 31 mold-related toxins across seven toxin classes from a single urine sample (Photo courtesy of RealTime Labs)

New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment

Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Collaboration combines cognitive assessment, blood testing, phlebotomy, and MRI to support faster diagnosis across the UK (Image Credt: Adobe Stock)

New UK Collaboration Expands Access to Integrated Alzheimer’s Diagnostic Testing

C2N Diagnostics and Cambridge Cognition have partnered with The Alzheimer’s Trust to create an integrated pathway aimed at supporting earlier and more accurate diagnosis of Alzheimer’s disease and related dementias.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.